Figure 3. Microglia protect mice from CNS infection.

Schematic describing setup of survival experiments (A and C) assessing PLX5622 treatment in relation to intracranial infection with 700 PFU MHV (day 0). Survival curve in B corresponds to data in A; survival curve in D corresponds to data in C. Data are representative of 2 to 5 independent experiments, with 5 to 15 mice per group. P < 0.05, by log-rank test when compared with control survival curves, except when PLX5622 treatment began on day 6. (E) Mice were treated with PLX5622 or control for 7 days and then inoculated intranasally with 3 × 10⁴ PFU rJ or N1347A. Data are combined from 2 independent experiments and represent a total of 10 mice per group. Survival curves were assessed for statistical significance by log-rank test. PLX5622-treated, rJ-infected mice had significantly shorter survival than did mice in all the other groups, while mock-treated, N1347A-infected mice survived significantly longer (P < 0.01) than did mice in the other 3 groups.